AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Triclosan is effective against a wide range of bacteria, including both gram-positive and gram-negative bacteria. It works by inhibiting the activity of an enzyme called enoyl-acyl carrier protein reductase, which is involved in bacterial fatty acid synthesis. This disrupts the bacterial cell membrane and prevents bacterial growth and reproduction.
Antifungal Activity: Triclosan also exhibits antifungal properties, making it effective against certain types of fungi that can cause infections in humans.
Skin Irritation: Triclosan has been associated with skin irritation and allergic reactions in some individuals, particularly those with sensitive skin. Prolonged or repeated exposure to products containing Triclosan may lead to redness, itching, dryness, or rash.
Hormonal Effects: There is evidence to suggest that Triclosan may have endocrine-disrupting effects, meaning it can interfere with hormone function in the body. Animal studies have shown that Triclosan can alter hormone levels and reproductive function, although the significance of these findings for humans is still not fully understood.
Antibiotic Resistance: Prolonged exposure to Triclosan may contribute to the development of antibiotic-resistant bacteria. Studies have shown that bacteria exposed to Triclosan may develop resistance not only to Triclosan itself but also to other antibiotics, reducing the effectiveness of antibiotic treatment.
Environmental Impact: Triclosan is persistent in the environment and can accumulate in waterways and ecosystems after being washed down the drain. It has been detected in water sources, sediment, and aquatic organisms, raising concerns about its potential ecological impact on aquatic ecosystems and wildlife.
Regulatory Restrictions: Due to concerns about its safety and environmental impact, the use of Triclosan in consumer products has been restricted or banned in some countries. In the United States, the Food and Drug Administration (FDA) banned the use of Triclosan in over-the-counter antiseptic wash products in 2016.
Alternatives: In response to the concerns surrounding Triclosan, many manufacturers have reformulated their products to remove Triclosan and replace it with alternative antibacterial agents or other ingredients. These alternatives are often perceived to be safer and have a lower environmental impact.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Enterococcus durans | Reduces |
species | Enterococcus faecalis | Reduces |
species | Enterococcus faecium | Reduces |
species group | Pseudomonas putida group | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
Acne | 0.3 | -0.3 | |
ADHD | 0.3 | 0.1 | 2 |
Allergic Rhinitis (Hay Fever) | 1 | 0.7 | 0.43 |
Allergies | 0.5 | 1.9 | -2.8 |
Allergy to milk products | 0.5 | 1.4 | -1.8 |
Alopecia (Hair Loss) | 0.2 | 0.2 | |
Alzheimer's disease | 1.9 | 1.1 | 0.73 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.2 | |
Ankylosing spondylitis | 0.9 | 0.6 | 0.5 |
Anorexia Nervosa | 0.7 | -0.7 | |
Antiphospholipid syndrome (APS) | 0.1 | 0.6 | -5 |
Asthma | 1 | 1.5 | -0.5 |
Atherosclerosis | 0.8 | 0.8 | |
Atrial fibrillation | 1.2 | 0.6 | 1 |
Autism | 0.9 | 2.1 | -1.33 |
benign prostatic hyperplasia | 1.1 | -1.1 | |
Biofilm | 0.1 | 1.3 | -12 |
Bipolar Disorder | 0.5 | 0.8 | -0.6 |
Brain Trauma | 0.6 | 0.6 | 0 |
Cancer (General) | 0.6 | 0.5 | 0.2 |
Carcinoma | 0.5 | 0.5 | 0 |
Celiac Disease | 1.6 | 1.8 | -0.13 |
Cerebral Palsy | 1 | 0.5 | 1 |
Chronic Fatigue Syndrome | 1.6 | 1.3 | 0.23 |
Chronic Kidney Disease | 0.8 | 0.5 | 0.6 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
Chronic Urticaria (Hives) | 0.2 | -0.2 | |
Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
Cognitive Function | 0.8 | 0.8 | |
Colorectal Cancer | 1.4 | 1.4 | 0 |
Constipation | 0.9 | 0.9 | |
Coronary artery disease | 0.5 | 1.3 | -1.6 |
COVID-19 | 2.4 | 3.9 | -0.63 |
Crohn's Disease | 1.7 | 1.4 | 0.21 |
Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
cystic fibrosis | 0.5 | 1.2 | -1.4 |
d-lactic acidosis (one form of brain fog) | 0.1 | -0.1 | |
deep vein thrombosis | 0.2 | 1.1 | -4.5 |
Denture Wearers Oral Shifts | 0.6 | 0.3 | 1 |
Depression | 2.3 | 0.9 | 1.56 |
Dermatomyositis | 0.1 | -0.1 | |
Eczema | 0.8 | 1 | -0.25 |
Endometriosis | 1 | 0.1 | 9 |
Epilepsy | 1.2 | 0.5 | 1.4 |
erectile dysfunction | 0.5 | 0.5 | |
Fibromyalgia | 0.7 | -0.7 | |
Functional constipation / chronic idiopathic constipation | 1.3 | 0.9 | 0.44 |
gallstone disease (gsd) | 0.5 | 0.5 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
Generalized anxiety disorder | 1 | 0.5 | 1 |
Gout | 1.6 | 0.1 | 15 |
Graves' disease | 0.5 | 0.8 | -0.6 |
Gulf War Syndrome | 0.3 | 0.3 | 0 |
Halitosis | 0.5 | 0.5 | |
Hashimoto's thyroiditis | 1.2 | 0.5 | 1.4 |
Heart Failure | 1 | 0.3 | 2.33 |
Hidradenitis Suppurativa | 0.5 | 0.7 | -0.4 |
High Histamine/low DAO | 0.1 | 0.9 | -8 |
hypercholesterolemia (High Cholesterol) | 0.7 | -0.7 | |
hyperglycemia | 1.1 | -1.1 | |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.8 | |
hypertension (High Blood Pressure | 1.7 | 1.9 | -0.12 |
Hypothyroidism | 0.1 | -0.1 | |
Hypoxia | 0.7 | 0.7 | |
IgA nephropathy (IgAN) | 0.5 | 1.2 | -1.4 |
Inflammatory Bowel Disease | 1.5 | 1.3 | 0.15 |
Insomnia | 0.5 | 1.6 | -2.2 |
Intelligence | 0.7 | 0.7 | |
Intracranial aneurysms | 0.5 | 0.5 | |
Irritable Bowel Syndrome | 1.7 | 1.9 | -0.12 |
ischemic stroke | 0.5 | 0.5 | 0 |
Liver Cirrhosis | 1.8 | 1.7 | 0.06 |
Long COVID | 1.8 | 0.9 | 1 |
Lung Cancer | 0.2 | 0.2 | |
Mast Cell Issues / mastitis | 0.7 | -0.7 | |
ME/CFS with IBS | 0.5 | 1 | -1 |
ME/CFS without IBS | 0.5 | 1.3 | -1.6 |
Menopause | 0.2 | 0.2 | |
Metabolic Syndrome | 2.4 | 2.1 | 0.14 |
Mood Disorders | 1.8 | 1.7 | 0.06 |
Multiple Sclerosis | 0.9 | -0.9 | |
Multiple system atrophy (MSA) | 0.2 | -0.2 | |
neuropathic pain | 0.5 | -0.5 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 0.5 | 1.6 |
NonCeliac Gluten Sensitivity | 0.5 | 0.5 | 0 |
Obesity | 1.9 | 1.5 | 0.27 |
obsessive-compulsive disorder | 1.5 | 1.1 | 0.36 |
Osteoarthritis | 0.7 | 0.6 | 0.17 |
Osteoporosis | 0.5 | 0.8 | -0.6 |
pancreatic cancer | 0.3 | 0.6 | -1 |
Parkinson's Disease | 1.4 | 1.6 | -0.14 |
Polycystic ovary syndrome | 1.4 | 0.8 | 0.75 |
primary biliary cholangitis | 0.5 | 0.4 | 0.25 |
Primary sclerosing cholangitis | 1.3 | 1.3 | |
Psoriasis | 0.7 | 1.2 | -0.71 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 2.9 | -1.23 |
Rosacea | 0.8 | -0.8 | |
Schizophrenia | 0.8 | 1.9 | -1.37 |
scoliosis | 0.1 | -0.1 | |
sensorineural hearing loss | 0.1 | -0.1 | |
Sjögren syndrome | 0.7 | -0.7 | |
Sleep Apnea | 0.5 | -0.5 | |
Slow gastric motility / Gastroparesis | 0.5 | 0.5 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.7 | 0.86 |
Stress / posttraumatic stress disorder | 1 | 1.3 | -0.3 |
Systemic Lupus Erythematosus | 1.7 | 0.3 | 4.67 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 1.9 | 0.6 | 2.17 |
Type 2 Diabetes | 2.3 | 1.5 | 0.53 |
Ulcerative colitis | 1.9 | 2.5 | -0.32 |
Unhealthy Ageing | 1.2 | 1.2 | |
Vitiligo | 0.7 | 0.2 | 2.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]